​​Frontage Clinical Services, an associate of Frontage Laboratories, has completed renovations to Frontage Clinical’s center in Secaucus, NJ, to now accommodate clinical studies on tobacco and nicotine-containing products.
 
The addition of two dedicated negative-pressure rooms that utilize displacement ventilation enables evaluation of subjects using a variety of investigational tobacco products, including combustible cigarettes and electronic nicotine delivery systems (ENDS), as well as smoking cessation therapies.
 
“Incorporation of these specialized clinical facilities enables us to perform clinical studies to assess product use behavior, abuse liability, product risk assessment and pharmacokinetic analyses,” said Lisa Diamond, president, Frontage Clinical. “Frontage Clinical is committed to providing the best services possible for each of its partners. The experienced clinical staff, PIs and scientists are eager to meet the ever-evolving needs of this industry.”
 
To complement Frontage Clinical’s operations expansion, Frontage Labs’ bioanalytical lab is developing a portfolio of assays to evaluate tobacco-specific biomarkers of exposure and potential harm. This allows Frontage to offer integrated services to their clients to provide high-quality data to meet regulatory submission requirements.
 
“Our bioanalytical facility is top-notch with an experienced team, specialized laboratory equipment, and dedicated space to perform these challenging biomarker assays,” said John Lin, executive vice president, bioanalytical and biologics services, Frontage Labs.